A 52-year-old woman with a 15-year history of type 2 diabetes mellitus presents with recurrent episodes of hypoglycemia despite a stable dose of metformin and glibenclamide. Her fasting blood glucose is 85 mg/dL, but she experiences sweating, tremor, and confusion 2–3 hours after meals. A mixed meal tolerance test shows: fasting glucose 90 mg/dL, 2-hour glucose 140 mg/dL, fasting insulin 18 mIU/L, and 2-hour insulin 65 mIU/L. Fasting glucagon is 120 pg/mL (normal 50–100 pg/mL). Which of the following best explains her hypoglycemic episodes?

Explanation

## Hypoglycemia in Long-Standing Type 2 Diabetes: Loss of Glucagon Counter-Regulation ### Clinical Presentation This patient exhibits **hypoglycemic unawareness** with postprandial hypoglycemia despite reasonable glycemic control (fasting 85 mg/dL, 2-hour 140 mg/dL). The key clue is the **elevated fasting glucagon (120 pg/mL)** despite low fasting glucose—indicating **loss of glucagon suppression** and impaired glucagon response to hypoglycemia. ### Pathophysiology: The Glucagon Counter-Regulatory Defect **Key Point:** In long-standing type 2 diabetes, **alpha cell dysfunction** develops, characterized by: 1. **Loss of glucose-sensing capability** in alpha cells 2. **Impaired glucagon suppression** during hyperglycemia (fasting glucagon remains elevated despite normal glucose) 3. **Blunted glucagon response** to hypoglycemia This is compounded by **sulfonylurea-induced insulin hypersecretion** (note: 2-hour insulin 65 mIU/L is markedly elevated). ### The Vicious Cycle ```mermaid flowchart TD A[Long-standing T2DM]:::outcome --> B[Alpha cell glucose sensing lost]:::outcome B --> C[Glucagon not suppressed in hyperglycemia]:::outcome C --> D[Glucagon not released in hypoglycemia]:::urgent E[Sulfonylurea]:::action --> F[Excessive insulin secretion]:::outcome F --> G[Unopposed hypoglycemic action]:::urgent D --> H[No counter-regulation to hypoglycemia]:::urgent G --> H H --> I[Severe hypoglycemia + unawareness]:::urgent ``` ### Why Glucagon Is Elevated at Baseline **High-Yield:** The **elevated fasting glucagon (120 pg/mL) despite normal fasting glucose (90 mg/dL)** is paradoxical and diagnostic of **alpha cell dysfunction**. Normally, glucagon is suppressed when glucose is normal. Here, the alpha cell has lost its glucose-sensing ability and cannot suppress glucagon appropriately. ### Metabolic Consequences | Phase | Insulin Level | Glucagon Level | Glucose Outcome | |-------|---------------|----------------|------------------| | **Fasting** | 18 mIU/L (elevated) | 120 pg/mL (inappropriately high) | 90 mg/dL (low-normal) | | **2 hours postprandial** | 65 mIU/L (very high) | ↓ (suppressed, but dysfunctional) | 140 mg/dL (modest rise) | | **Hypoglycemia stimulus** | High (from sulfonylurea) | **Blunted response** (alpha cell dysfunction) | **Severe hypoglycemia** | **Clinical Pearl:** The combination of **elevated baseline glucagon + elevated postprandial insulin + hypoglycemic episodes** is the hallmark of **"brittle" diabetes**—a state where loss of alpha cell counter-regulation meets excessive beta cell (or exogenous) insulin secretion. ### Mechanism of Hypoglycemic Unawareness 1. **Impaired glucagon response** → no hepatic glucose output during hypoglycemia 2. **Excessive insulin from sulfonylurea** → unopposed glucose lowering 3. **Chronic hypoglycemia** → blunted sympathetic (epinephrine) response → loss of warning symptoms **Warning:** This patient is at high risk for **severe hypoglycemia and seizures**. Sulfonylureas should be discontinued or dose-reduced, and glucagon emergency kits should be prescribed.